Dynavax Acquired by Sanofi in $2.2 Billion Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Yahoo Finance
- Acquisition Announcement: Sanofi has announced its acquisition of California-based Dynavax for $2.2 billion, which is expected to enhance its vaccine portfolio, particularly with Dynavax's hepatitis B vaccines and a shingles vaccine in development, thereby increasing market competitiveness.
- Stock Price Surge: Following the acquisition news, Dynavax's stock soared by 38.2%, reflecting positive market sentiment towards the deal and potentially attracting more investor interest in the biotechnology sector.
- Market Impact: This acquisition will not only expand Sanofi's vaccine product line but may also alter the competitive landscape in the vaccine market, especially in the hepatitis and weight-loss drug sectors, driving future growth for the company.
- Industry Trend: With increasing merger and acquisition activity in the pharmaceutical industry, Sanofi's acquisition strategy highlights the intent of large pharmaceutical companies to enhance their product offerings and market share in response to intensifying competition.
DVAX
$15.38+Infinity%1D
Analyst Views on DVAX
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 21.00 USD with a low forecast of 11.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 11.130
Low
11.00
Averages
21.00
High
32.00
Current: 11.130
Low
11.00
Averages
21.00
High
32.00
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
